Recent News

• 01.11.2026 - Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
• 12.18.2025 - Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
• 12.06.2025 - Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
• 11.12.2025 - Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
• 11.04.2025 - Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
• 11.03.2025 - Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Recent Filings

• 01.15.2026 - 144 Report of proposed sale of securities
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.11.2025 - 8-K Current report
• 11.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.04.2025 - 8-K Current report
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]